Compare Heron Therapeutics Inc (HRTX) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Schwab US Dividend Equity ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Schwab US Dividend Equity ETF trades at $33.08 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 1625.6× Heron Therapeutics Inc's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| HRTX | SCHD | |
|---|---|---|
Market Cap | $68.01M | $110.56B |
Volume | 1,891,941 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $35.21 |
52-Week Low | $0.27 | $26.44 |
Typical Hold Time | 35 Days | 62 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
SCHD trades at $32.65, down 0.61% with a bearish technical signal from moving averages. Recent news highlights its strong 2026 performance against the S&P 500 and a recent dividend declaration. The ETF's defensive dividend strategy faces pressure from rising interest rates, contributing to recent price weakness from August highs near $35.
The outlook balances income growth potential against interest rate sensitivity. Near-term support at $32 provides a key level to watch, while the dividend-focused approach offers stability for long-term investors despite current technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
